Name | Ralaniten |
---|---|
Synonyms |
(2R)-3-[4-(2-{4-[(2S)-3-Chloro-2-hydroxypropoxy]phenyl}-2-propanyl)phenoxy]-1,2-propanediol
1,2-Propanediol, 3-[4-[1-[4-[(2S)-3-chloro-2-hydroxypropoxy]phenyl]-1-methylethyl]phenoxy]-, (2R)- WC830G6O4X MFCD30502912 |
Description | Ralaniten (EPI-506) is a novel small-molecule inhibitor of androgen receptor (AR) N-terminal domain inhibitor for the treatment of advanced prostate cancer; AR NTD-targeting agents have the potential to overcome shortcomings of current hormonal therapies by inhibiting all forms of AR-mediated transcriptional activity, and as a result, may affect a broader AR population including mutational and splice variant ARs. Prostate Cancer Phase 2 Clinical |
---|---|
References | References 1. Antonarakis ES, et al. Oncologist. 2016 Dec;21(12):1427-1435. View Related Products by Target Estrogen Receptor/ERR Prostate Cancer |
Density | 1.2±0.1 g/cm3 |
---|---|
Boiling Point | 601.0±55.0 °C at 760 mmHg |
Molecular Formula | C21H27ClO5 |
Molecular Weight | 394.889 |
Flash Point | 317.2±31.5 °C |
Exact Mass | 394.154694 |
LogP | 2.98 |
Vapour Pressure | 0.0±1.8 mmHg at 25°C |
Index of Refraction | 1.571 |
Hazard Codes | Xn |
---|